Geron’s developing cancer treatment meets midstage study goals

Geron cancer drug meets midstage study goals

MENLO PARK, Calif. — Biotechnology company Geron Corp. said Tuesday its developing cancer treatment GRNVAC1 met safety and tolerability goals in a midstage study.

The drug candidate is actually a developing vaccine, aimed at prompting the immune system to fight tumor cells. The study involves patients with acute myelogenous leukemia, a type of blood and bone marrow cancer.

Shares of Geron rose 12 cents, or 2 percent, to $6.02 in after-hours trading after rising 12 cents to close at $5.90 during the regular trading session.